Radiesse^® (+) with integral 0.3% Lidocaine (Radiesse^® Plus) from Merz North America, US affiliate of the global Merz Pharma Group, has received FDA approval and is now available to US physicians. Radiesse^® (+) provides the immediate lift of wrinkles and folds, stimulation of natural collagen production, and the lasting results that patients and physicians expect from Radiesse^®, as well as providing patients significant reduction in pain due to the addition of lidocaine^1-4.

Radiesse^® (+) injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). Radiesse^® (+) is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

“With the introduction of Radiesse^® (+), Merz addresses the need of restoring lost facial volume while reliably enhancing patient comfort and eliminating the need for in-office lidocaine mixing. We are excited to provide our physician customers with yet another Merz technology to help deliver positive patient outcomes and treatment experiences,” stated Jim Hartman, Vice President and Head of U.S. Aesthetics/OTC for Merz North America.

“In my practice, comfort during treatment is a concern for the majority of the patients that walk through the door,” stated Dr. Z. Paul Lorenc, MD, FACS. “Radiesse (+) allows physicians to treat/correct wrinkles and folds with the same effective product we’ve used for the past decade, while providing patients with the enhanced comfort they are looking for.” In addition to his work as a board-certified aesthetic plastic surgeon in private practice in New York City, Dr. Lorenc is actively involved in research, development and advancement of new aesthetic surgical and non-surgical techniques and procedures.

Radiesse^® (+) is a robust filler providing high elasticity (G’) and viscosity, according to Merz. In a clinical study, 101 patients received Radiesse^® on one side of the face and Radiesse^® (+) on the other side of the face. Patients rated their pain on a scale of 0 to 10. On the scale, 0 was no pain and 10 was very severe pain. Immediately after injection, patients rated their pain about 6.7 on a scale of 0 to 10 for the side of the face injected with Radiesse^® compared to about 2.3 on the same scale for the side of the face treated with Radiesse^® (+). Sixty minutes after treatment, patients rated their pain about 1.1 on a scale of 0 to 10 for the side of the face injected with Radiesse^® compared to about 0.3 on the same scale for the side of the face treated with Radiesse^® (+).